Euroapi S.A. (0EAP.L)
| Previous close | 15.61 |
| Open | 15.78 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 15.78 - 15.90 |
| 52-week range | 9.55 - 18.92 |
| Volume | |
| Avg. volume | 71,783 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 31 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Globe NewswireEUROAPI is moving ahead with its FOCUS-27 plan, setting the foundations for future profitable growth1
Press Release Agreement with Sanofi on a 200 M€ investment through a Perpetual Subordinated Hybrid Bond, upon the completion of the ongoing discussions to amend and extend the current Revolving Credit Facility75 to 80 M€ annual run-rate incremental Core EBITDA targeted by the end of 2027, driven by the end of higher value API and CDMO offering, a streamlined industrial footprint, and significant cost reductions Brindisi site expected to progressively resume shipments and production during Q3 202
GlobeNewswireEUROAPI and Priothera enter into CDMO collaboration to advance oncology project
Press Release EUROAPI and Priothera, a biotechnology company specializing in the treatment of hematological malignancies and the improvement of CAR-T cell therapies, have signed a 5-year CDMO agreementEUROAPI will develop and industrialize the manufacturing process of innovative complex molecule for blood cancers Paris – June 18, 2024 – EUROAPI announces today the implementation of a 5-year development and manufacturing agreement with Priothera, a biotechnology company specializing in molecules
- Globe Newswire
Market update : FOCUS-27 transformation project financing
Press release Paris – June 6, 2024 – EUROAPI informs that it has decided to be assisted by a mandataire ad hoc in its discussions initiated in February 2024 regarding the mid-term and long-term financing of its FOCUS-27 strategic transformation project. The mandat ad hoc is an amicable procedure launched at the company's initiative and conducted within a confidential and legally secured framework. EUROAPI has appointed such an independent third party proactively to accelerate the outcome of the
